Lessons from a pilot study of transfer factor in chronic fatigue syndrome

Biotherapy

Volumn 9, Issue 1-3, 1996, Pages 87-90

  De Vinci, Caterina ^a,f   Le Vine, Paul H ^b   Pizza, Giancarlo ^a   Fudenberg, Hugh H ^c   Orens, Perry ^a   Pearson, Gary ^d   Viza, Dimitri ^e  

^a 1st Division   (Italy)

^b GEORGETOWN UNIVERSITY   (United States)

^c Neurolmmuno Therapeutics Foundation   (United States)

^d GreatNeck   (United States)

^e CNRS   (France)

^f UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

chronic fatigue syndrome; CMV; EBV; herpes viruses; HHV 6; transfer factor

Indexed keywords

PLACEBO; TRANSFER FACTOR; VIRUS ANTIBODY;

ADULT; ANIMAL CELL; ANTIBODY RESPONSE; CHRONIC FATIGUE SYNDROME; CLINICAL ARTICLE; CLINICAL FEATURE; CLINICAL TRIAL; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; EPSTEIN BARR VIRUS; FEMALE; HUMAN; HUMAN HERPESVIRUS 6; LYMPHOCYTE; MALE; MOUSE; NONHUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; SEROLOGY;

EID: 0029749638     PISSN: 0921299X     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF02628663     Document Type: Conference Paper

References (14)

1. Pukuda K, Straus SE, Hickie I, Sharpe MC, Dobbins JG & Komaroff A. International Chronic Fatigue Syndrome Study Group. The Chronic fatigue syndrome: a comprehensive approach to its definition. Ann Int Med 1994; 121: 953-9.
2. Nkrumah F. Pizza G, Viza D, Phillips J, De Vinci C& Levine PH. Regression of progressive lymphadenopathy in a young child with acute cytomegalovirus (CMV) infection following the administration of transfer factor with specific anti-CMV activity. Lymphokine Res 1985; 4: 237-41.
3. Neequaye J, Viza D, Pizza D, Levine PH, De VinciC, Ablashi DV, Biggar RJ & Nkrumah FK. Specific transfer factor with activity against Epstein-Barr virus reduces late relapse in endemic Burkitt's lymphoma. Anticanc R 1990; 10: 1 ISSUS?.
4. Viza D. Vich JM, Phillips J & Rosenfeld F. Orally administered specific transfer factor for the treatment of herpes infections. Lymphokine Res 1985; 4: 27-30.
5. Rosenfeld F, Viza D, Phillips J, Vich JM, Binet O & AronBrunetière R. Traitement des infections herpétiques par le facteur de transfert. Presse Méd 1984; 13: 537-540.
6. Meduri R, Campos E, Scorolli L, De Vinci C, Pizza G & Viza D. Transfer Factor in recurrent ocular herpes. Biotherapy, this issue.
7. Pizza G, Viza D, De Vinci C, Palareti A, Cuzzocrea D, Fornarola F & Baricordi OR. Orally administered HSV-specific Transfer Factor (TF) prevents genital and/or labial herpes relapses. Biotherapy, this issue.
8. Viza D, Vich JM, Phillips J, Rosenfeld F & Davies DAL. Specific transfer factor protects mice against lethal challenge with herpes simplex virus. Cell Immun 1986; 100: 555-562.
9. Buchwald D, Cheney PR, Peterson DL, Henry B, Wonnslcy SB, Geiger A, Ablashi DV, Salahuddin SZ, Saxinger C, Biddle R, KiUcinis R, Jolcsz FA, Folks T, Balachandran N, Gallo RD & Komaroff AL. A chronic illness characterized by fatigue, neuralgia, and immunologie disorders and active herpesvirus6 type infection. Ann Int Med 1992; 116: 103-113.
10. Pizza G, Viza D, Ablashi DV, Jerome L, Armstrong G& Levine PH. The possible use of specific transfer factor in the treatment of patients with nasopharyngeal carcinoma. In:Grundman E, Krueger GRF, Ablashi DV eds, Nasopharyngeal Carcinoma. Stuttgart: Gustav Fisher-Veriag Editor, 1981, 301-307.
11. Viza D, Goust JM, Moulias R, Trejdosiewicz LK, Collard A & Mueller-Berat N. 'In vitro' production of transfer factor by lymphoblastoid cell lines. Transplan P 1975; VII (suppl. 1): 329-333.
12. Ablashi DV, Levine PH, Kaplan M, DeVrnci C, Whitman JE, Pizza G & Viza D. In Vivo Effectiveness of and HHV-6 transfer factor in two patients with chronic fatigue syndrome (CFS) Biotherapy, (his issue.
13. Levine PH: The use of transfer factors in chronic fatigue syndrome: prospects and problems. Biotherapy, this issue.
14. Straus SE, Dale JK, Tobi M, et al. Acyclovir treatment of the chronic fatigue syndrome: lack of efficacy in a placebocontrolled trial. N Eng J Med 1988; 319: 1692-98.